174 related articles for article (PubMed ID: 26862056)
1. A Japanese family with X-linked sideroblastic anemia affecting females and manifesting as macrocytic anemia.
Katsurada T; Kawabata H; Kawabata D; Kawahara M; Nakabo Y; Takaori-Kondo A; Yoshida Y
Int J Hematol; 2016 Jun; 103(6):713-7. PubMed ID: 26862056
[TBL] [Abstract][Full Text] [Related]
2. Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia.
Morimoto Y; Chonabayashi K; Kawabata H; Okubo C; Yamasaki-Morita M; Nishikawa M; Narita M; Inagaki A; Nakanishi K; Nagao M; Takaori-Kondo A; Yoshida Y
Blood Adv; 2022 Feb; 6(4):1100-1114. PubMed ID: 34781359
[TBL] [Abstract][Full Text] [Related]
3. Absent phenotypic expression of X-linked sideroblastic anemia in one of 2 brothers with a novel ALAS2 mutation.
Cazzola M; May A; Bergamaschi G; Cerani P; Ferrillo S; Bishop DF
Blood; 2002 Dec; 100(12):4236-8. PubMed ID: 12393718
[TBL] [Abstract][Full Text] [Related]
4. X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley.
Cotter PD; Rucknagel DL; Bishop DF
Blood; 1994 Dec; 84(11):3915-24. PubMed ID: 7949148
[TBL] [Abstract][Full Text] [Related]
5. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia.
Bekri S; May A; Cotter PD; Al-Sabah AI; Guo X; Masters GS; Bishop DF
Blood; 2003 Jul; 102(2):698-704. PubMed ID: 12663458
[TBL] [Abstract][Full Text] [Related]
6. X-linked sideroblastic anaemia in a female fetus: a case report and a literature review.
Nzelu D; Shangaris P; Story L; Smith F; Piyasena C; Alamelu J; Elmakky A; Pelidis M; Mayhew R; Sankaran S
BMC Med Genomics; 2021 Dec; 14(1):296. PubMed ID: 34930268
[TBL] [Abstract][Full Text] [Related]
7. Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females.
Cazzola M; May A; Bergamaschi G; Cerani P; Rosti V; Bishop DF
Blood; 2000 Dec; 96(13):4363-5. PubMed ID: 11110715
[TBL] [Abstract][Full Text] [Related]
8. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts.
Cotter PD; May A; Fitzsimons EJ; Houston T; Woodcock BE; al-Sabah AI; Wong L; Bishop DF
J Clin Invest; 1995 Oct; 96(4):2090-6. PubMed ID: 7560104
[TBL] [Abstract][Full Text] [Related]
9. Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis.
Cotter PD; May A; Li L; Al-Sabah AI; Fitzsimons EJ; Cazzola M; Bishop DF
Blood; 1999 Mar; 93(5):1757-69. PubMed ID: 10029606
[TBL] [Abstract][Full Text] [Related]
10. Late-onset X-linked sideroblastic anemia following hemodialysis.
Furuyama K; Harigae H; Kinoshita C; Shimada T; Miyaoka K; Kanda C; Maruyama Y; Shibahara S; Sassa S
Blood; 2003 Jun; 101(11):4623-4. PubMed ID: 12531813
[TBL] [Abstract][Full Text] [Related]
11. Disparate phenotypic expression of ALAS2 R452H (nt 1407 G --> A) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma.
Barton JC; Lee PL
Blood Cells Mol Dis; 2006; 36(3):342-6. PubMed ID: 16540354
[TBL] [Abstract][Full Text] [Related]
12. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns.
Aivado M; Gattermann N; Rong A; Giagounidis AA; Prall WC; Czibere A; Hildebrandt B; Haas R; Bottomley SS
Blood Cells Mol Dis; 2006; 37(1):40-5. PubMed ID: 16735131
[TBL] [Abstract][Full Text] [Related]
13. A Novel
Lee JS; Gu J; Yoo HJ; Koh Y; Kim HK
Ann Clin Lab Sci; 2017 May; 47(3):319-322. PubMed ID: 28667034
[TBL] [Abstract][Full Text] [Related]
14. [Congenital sideroblastic anemia-a new family with identification of K156E mutation of ALAS2 gene and literature review].
Cui R; Xu Z; Qin T; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):142-6. PubMed ID: 24606657
[TBL] [Abstract][Full Text] [Related]
15. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase.
Cox TC; Bottomley SS; Wiley JS; Bawden MJ; Matthews CS; May BK
N Engl J Med; 1994 Mar; 330(10):675-9. PubMed ID: 8107717
[TBL] [Abstract][Full Text] [Related]
16. Arg452 substitution of the erythroid-specific 5-aminolaevulinate synthase, a hot spot mutation in X-linked sideroblastic anaemia, does not itself affect enzyme activity.
Furuyama K; Harigae H; Heller T; Hamel BC; Minder EI; Shimizu T; Kuribara T; Blijlevens N; Shibahara S; Sassa S
Eur J Haematol; 2006 Jan; 76(1):33-41. PubMed ID: 16343269
[TBL] [Abstract][Full Text] [Related]
17. Congenital sideroblastic anemia model due to ALAS2 mutation is susceptible to ferroptosis.
Ono K; Fujiwara T; Saito K; Nishizawa H; Takahashi N; Suzuki C; Ochi T; Kato H; Ishii Y; Onodera K; Ichikawa S; Fukuhara N; Onishi Y; Yokoyama H; Yamada R; Nakamura Y; Igarashi K; Harigae H
Sci Rep; 2022 May; 12(1):9024. PubMed ID: 35637209
[TBL] [Abstract][Full Text] [Related]
18. A novel heterozygous ALAS2 mutation in a female with macrocytic sideroblastic anemia resembling myelodysplastic syndrome with ring sideroblasts: a case report and literature review.
Fujiwara T; Fukuhara N; Ichikawa S; Kobayashi M; Okitsu Y; Onishi Y; Furuyama K; Harigae H
Ann Hematol; 2017 Nov; 96(11):1955-1957. PubMed ID: 28840292
[No Abstract] [Full Text] [Related]
19. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations.
Campagna DR; de Bie CI; Schmitz-Abe K; Sweeney M; Sendamarai AK; Schmidt PJ; Heeney MM; Yntema HG; Kannengiesser C; Grandchamp B; Niemeyer CM; Knoers NV; Swart S; Marron G; van Wijk R; Raymakers RA; May A; Markianos K; Bottomley SS; Swinkels DW; Fleming MD
Am J Hematol; 2014 Mar; 89(3):315-9. PubMed ID: 24166784
[TBL] [Abstract][Full Text] [Related]
20. X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the β-subunit of succinyl-CoA synthetase (SUCLA2).
Bishop DF; Tchaikovskii V; Hoffbrand AV; Fraser ME; Margolis S
J Biol Chem; 2012 Aug; 287(34):28943-55. PubMed ID: 22740690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
